Logo

Illumina: Jay Flatley

Jan 15, 2020

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.